CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Nexalis Therapeutics Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Nexalis Therapeutics Ltd
Level 9, 505 Little Collins Street
Phone: +61 86784091p:+61 86784091 MELBOURNE, VIC  3000  Australia Ticker: LSHLSH
Business Summary
Nexalis Therapeutics Ltd, formerly InhaleRx Limited, is an Australia-based clinical stage drug development company. The Company is focused on developing onset, inhaled therapies to address unmet medical needs in the pain management and mental health sectors. The Company is focused on the development of IRX-211 to treat Breakthrough Cancer Pain (BTcP), and IRX-616a to treat panic disorders (PD) and SRX-25 for the treatment of Treatment-Resistant Depression (TRD). The Company operates through segment development of medicinal drug-device products to address unmet medical needs. Its IRX-211 focuses on the management of BTcP with non-opioid, onset inhaled therapy. The Phase I clinical trials for IRX-211 have been completed. Its IRX-616a is an approved inhaled medication for panic disorder, offering a novel treatment avenue.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202512/31/2024Yes----

Industries
SIC Code Description
3845 Electromedical and electrotherapeutic apparatus
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Chairman of the Board SeanWilliams 7/26/2021 7/26/2021
Chief Executive Officer DarrylDavies 9/27/2022 7/20/2021
Chief Scientific Officer RobJenny 9/27/2022 9/27/2022
3 additional Officers and Directors records available in full report.

Business Names
Business Name
IRX
LSH
NX1

General Information
Outstanding Shares: 227,854,872 (As of 12/1/2025)
Shareholders: 568
Stock Exchange: ASX


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, February 24, 2026